3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
31
Hodgkin Disease
19
Lymphoma
9
Uveal Melanoma
5
Neoplasms
4
Sarcoma
3
Neoplasm Metastasis
3
Leiomyosarcoma
3
Skin Neoplasms
2
Skin Diseases
1
Sarcoma, Synovial
1
Recurrence
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neurofibrosarcoma
1
Lymphoma, T-Cell, Peripheral
1
Hematologic Diseases
1
HIV Infections
1
Interventions
pembrolizumab
120
Cisplatin
26
Carboplatin
24
Paclitaxel
21
Docetaxel
17
lenvatinib
15
Pemetrexed
12
Fluorouracil
12
Saline Solution
11
Capecitabine
10
epacadostat
8
Oxaliplatin
7
Gemcitabine
7
Leucovorin
5
Cetuximab
5
130-nm albumin-bound paclitaxel
5
olaparib
4
enzalutamide
4
Irinotecan
4
Bevacizumab
4
Albumin-Bound Paclitaxel
4
trifluridine tipiracil drug combination
3
regorafenib
3
Prednisone
3
Dexamethasone
3
Radiotherapy
2
Ipilimumab
2
Glucose
2
Etoposide
2
Doxorubicin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Dacarbazine
×
Clear all
NCT01704287
2020-05-18
KEYNOTE 002
Merck Sharp & Dohme LLC
Phase 2
Completed
540 enrolled
20 charts